<DOC>
	<DOCNO>NCT01348438</DOCNO>
	<brief_summary>The purpose study evaluate safety clinical performance Engager Transcatheter Aortic Valve Implantation System patient severe aortic valve stenosis high risk surgical valve replacement .</brief_summary>
	<brief_title>Transapical Implantation Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Severe aortic stenosis define one follow Doppler echocardiography : mean gradient &gt; 40 mmHg ; max velocity &gt; 4m/s ; aortic valve area ≤ 0.8 cm2 . 2 . Symptoms related aortic valve disease , NYHA Functional Class II great . 3 . Logistic EuroSCORE predict risk mortality ≥20 % , comorbidity judge investigator pose absolute relative contraindication conventional aortic valve replacement . 4 . Patient indicate aortic valve implantation biological prosthesis ( tissue valve ) accordance 2007 European Society Cardiology ( ESC ) Guidelines management valvular heart disease . 5 . Age ≥ 18 year . 6 . Echocardiographically determine aortic annulus diameter ≥19 mm ≤ 26 mm longaxis view . 1 . Congenital unicuspid bicuspid aortic valve . 2 . Severe eccentricity calcification , define calcium deposit large 6mm diameter . 3 . Echocardiographic evidence intracardiac mass , thrombus , vegetation . 4 . Left ventricular ejection fraction &lt; 25 % , determine contrast ventriculography , echocardiography radionuclide angiography contrast ventriculography available 5 . Hypertrophic obstructive cardiomyopathy . 6 . Patients life expectancy le 12 month due underlying noncardiac comorbid disease . 7 . Known hypersensitivity contraindication adequately control premedication study medication material , contrast medium Nitinol . 8 . Sepsis acute endocarditis . 9 . Blood dyscrasia acute anemia , leucopenia , thrombocytopenia ; bleed diathesis , coagulopathy . 10 . Renal insufficiency assess creatinine &gt; 2.5 mg/dl and/or end stage renal disease require chronic dialysis . 11 . Active peptic ulcer GI bleeding within 3 month plan index procedure . 12 . Untreated clinically significant coronary artery disease require revascularization . 13 . Cardiogenic shock , suspect cardiogenic shock , hemodynamic instability require inotropic support mechanical heart assistance . 14 . Significant aortic disease , include abdominal thoracic aortic aneurysm , define maximal luminal diameter 5 cm great . 15 . Need emergency surgery , cardiac noncardiac . 16 . History myocardial infarction last 6 week . 17 . History TIA CVA last 6 month . 18 . Therapeutic invasive cardiac procedure , exception aortic balloon valvuloplasty , perform within 30 day plan date valve implantation , 6 month case drugeluting stent . 19 . Preexisting prosthetic heart valve prosthetic ring position . 20 . Mitral regurgitation great 2+ angiography moderate echocardiography . 21 . Patient refuse blood transfusion . 22 . Patient currently enrol another investigational device drug trial may influence outcome trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>high risk</keyword>
	<keyword>surgical valve replacement</keyword>
</DOC>